BRCA2 and breast cancer: In a subgroup analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) trial [54], Tamoxifen was found to reduce the incidence of breast cancer in healthy BRCA2 mutation carriers but not in BRCA1 carriers when started at the age 35 years or older[55].